banner

Posts tagged as: FDA meeting back to homepage

Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug(0)

Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate.  Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More

FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug(0)

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™.  As previously disclosed on April 16, 2012, the Company had Read More

Cellceutix to Meet with FDA on New Psoriasis Drug Cellceutix to Meet with FDA on New Psoriasis Drug(0)

This one day might be the story called “The Little Biotech That Could”.  Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism).   The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.